Scientists finally uncover why promising cancer drugs keep failing

sciencedaily - Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don’t actually do the same job. Instead, BRD2 acts l…

AI Summary: Scientists uncovered a cellular survival mechanism that helps tumors withstand DNA damage, offering a concrete explanation for why numerous promising anti‑cancer agents stumble in clinical trials. The discovery exposes a resistance pathway that blunts drug efficacy and suggests new targets to sensitize tumors and potentially revive stalled therapies — which, yes, might finally save some development budgets.

• BET inhibitor paradox — BRD2 preps, BRD4 triggers gene activation (3)
• OTHER — Diverse resistance mechanisms and maps of tumor adaptation (6)
• Replication-fork rescue — Tumors patch DNA breaks to survive therapy (3)
• RNA regulation vulnerabilities — RNA editing and noncoding RNAs expose targets (3)
• All Other Stories

BET inhibitor paradox — BRD2 preps, BRD4 triggers gene activation

OTHER — Diverse resistance mechanisms and maps of tumor adaptation

Replication-fork rescue — Tumors patch DNA breaks to survive therapy

RNA regulation vulnerabilities — RNA editing and noncoding RNAs expose targets

All Other Stories